Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease

被引：17

作者：

Alkhateeb A. ^{[1
]}

Zubritsky L. ^{[2
]}

Kinsman B. ^{[1
]}

Leitzel K. ^{[2
]}

Campbell-Baird C. ^{[2
]}

Ali S.M. ^{[2
,3
]}

Connor J. ^{[1
]}

Lipton A. ^{[2
]}

机构：

[1] Department of Neurosurgery, Pennsylvania State University Hershey Medical Center, Hershey

[2] Division of Hematology-Medical Oncology, Pennsylvania State University Hershey Medical Center, Hershey, PA 17033

[3] Lebanon VA Medical Center, Lebanon

来源：

Journal of Gastrointestinal Cancer | 2014年 / 45卷 / 2期

关键词：

CRP; Inflammation; Pancreatic cancer; Serum ferritin;

D O I：

10.1007/s12029-013-9564-9

中图分类号：

学科分类号：

摘要：

Purpose: Cancer-associated inflammation plays a driver role in pancreatic tumor development and progression. Moreover, recent studies have implicated the inflammatory tumor microenvironment in modulating therapy response and inducing resistance. The aim of this study is to investigate the prognostic and predictive value of the inflammatory biomarkers serum ferritin and C-reactive protein (CRP) in advanced pancreatic cancer patients. Methods: We measured pretreatment serum ferritin and CRP levels in 159 patients with inoperable pancreatic cancer participating in a phase III trial. Results: Serum ferritin and CRP levels were examined for correlations with overall survival using Kaplan-Meier analysis. When analyzed on a categorical basis, patients with higher ferritin (>median) or CRP (>25th percentile) had shorter overall survival. Moreover, the two biomarkers were not correlated suggesting independent mechanisms of production and release. However, when patients were evaluated by their ferritin and CRP levels, only patients with elevation in both inflammatory biomarkers showed a significant decrease in overall survival. Conclusions: Serum ferritin and CRP are independent prognostic factors for shorter survival in patients with inoperable pancreatic tumors. Moreover, the evaluation of patients based on both biomarkers suggested that their prognostic value, although independent, reflected the broader state of cancer-associated inflammation. Thus, serum ferritin and CRP should be further explored as clinical biomarkers. © 2014 Springer Science+Business Media.

引用

页码：161 / 167

页数：6

共 43 条

[1]

Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012, CA Cancer J Clin, 62, 1, pp. 10-29, (2012)

[2]

Parker S.L., Tong T., Bolden S., Wingo P.A., Cancer statistics, 1996, Ca-A Cancer Journal for Clinicians, 46, 1, pp. 5-27, (1996)

[3]

Steinberg W., The clinical utility of the CA 19-9 tumor-associated antigen, American Journal of Gastroenterology, 85, 4, pp. 350-355, (1990)

[4]

Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast Jr. R.C., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer, Journal of Clinical Oncology, 24, 33, pp. 5313-5327, (2006)

[5]

Rocha L.C.M.S., Savarese D., Bruckner H., Dudek A., Eckardt J., Hainsworth J., Yunus F., Lester E., Miller W., Saville W., Elfring G.L., Locker P.K., Compton L.D., Miller L.L., Green M.R., Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer, Journal of Clinical Oncology, 20, 5, pp. 1182-1191, (2002)

[6]

Lowenfels A.B., Maisonneuvi P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andren-Sandberg A., Domellof L., Di F.V., Pederzoli P., Lohr-Happe A., Krag E., Melton III I.J., Boyle P., Pitchumoni C.S., Wynn P.S., Pancreatitis and the risk of pancreatic cancer, New England Journal of Medicine, 328, 20, pp. 1433-1437, (1993)

[7]

Daniluk J., Liu Y., Deng D., Chu J., Huang H., Gaiser S., Et al., An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice, J Clin Invest, 122, 4, pp. 1519-1528, (2012)

[8]

Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., Et al., Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence, Cancer Cell, 19, 6, pp. 728-739, (2011)

[9]

Fukuda A., Wang S.C., Morris J.P., Folias A.E., Liou A., Kim G.E., Et al., Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression, Cancer Cell, 19, 4, pp. 441-455, (2011)

[10]

Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Et al., EMT and dissemination precede pancreatic tumor formation, Cell, 148, 1-2, pp. 349-361, (2012)

← 1 2 3 4 5 →